- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Feyi Olopade Ayodele Highlights How CancerIQ Helps With Genetic Testing
CancerIQ is reducing barriers that make it difficult to utilize genetic testing to predict or pre-empt a patient’s cancer diagnosis, explained Feyi Olopade Ayodele, MBA, chief executive officer at CancerIQ.
CancerIQ is reducing barriers that make it difficult to utilize genetic testing to predict or pre-empt a patient’s cancer diagnosis, explained Feyi Olopade Ayodele, MBA, chief executive officer at CancerIQ.
Transcript
How is CancerIQ working to make genetic services more practical in predicting or preventing cancer?
So, CancerIQ is making it more practical to start predicting and pre-empting cancer by really trying to reduce some of the barriers that are really holding the industry back today. The first of those challenges is really knowledge. You know, to connect the dots on people’s family history, and their genetic testing information. Really stuff that the provider can’t do with the naked eye. So, it’s really through our software that we can automate the decisions that need to be made on the basis of that information, and make it relatively easy for the physician, who, quite frankly, didn’t study genetics when they were in medical school.
The second way that CancerIQ makes it practical for people to do this in routine care is being really mindful of the clinical workflow. Unfortunately, people are today using systems that are primarily oriented for billing and logging of information. And CancerIQ works really well with those systems in being a layer of intelligence on top of that. So, how we actually integrate into your everyday clinical workflow is really connecting to the systems that already exist but putting that layer of intelligence on top of it.
Advancing HIV Care With Doravirine and Islatravir: Q&A With Amy Colson, MD, MPH
March 12th 2025New data from the MK-8591A-051 and MK-8591A-052 trials, both investigating the efficacy and safety of 100-mg doravirine and 0.25-mg islatravir as a once-daily 2-drug regimen for virologically suppressed people living with HIV-1, were presented today by Amy Colson, MD, MPH.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Global Status of HIV/AIDS Pandemic Takes Center Stage in Opening Session
March 10th 2025The Conference on Retroviruses and Opportunistic Infections 2025 opened with a session dedicated to informing attendees about the progress, and lack of progress, that has been made in the fight against the HIV pandemic given the current political climate.
Read More
HIVconsvX Vaccine Shows Safety, Immune Response in People on ART
March 10th 2025This research on a T-cell–targeting vaccine in HIV has implications for future study design to incorporate consideration of age and years on antiretroviral therapy (ART) to evaluate the level of immune reconstitution.
Read More
